CORNELIUS, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (NASDAQ: AMOD) subsidiary Alpha Modus, Corp. announced that it has filed a federal patent-infringement lawsuit in the U.S. District Court for the Central District of California against Adroit Worldwide Media, Inc. (“AWM”), alleging unauthorized use of Alpha Modus’s patented retail-intelligence and cashierless-checkout technologies. Patent-Infringement-Complaint-Case-No.-825-cv-02471. The lawsuit asserts infringement of four U.S. p ...

Recognizes Groundbreaking Wafer-Scale SWIR Photodetector PlatformGOLETA, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum computing, today announced that it has received a 2025 LEAP Award from Design World in the category of Advanced Materials for the company’s Wafer-Scale SWIR Photodetector Platform. “We are honored to receive ...

核心观点 - 公司公布2025年第三季度强劲财务业绩，并上调2025年全年业绩指引 [1][2] - 第三季度投资组合收款（Portfolio Receipts）实现两位数增长，同比增长11%至8.14亿美元 [3][5][8] - 公司在过去几个月资本配置活跃，年内资本配置总额达到20亿美元，并通过交易扩大了投资组合 [2][6] - 公司预计2025年全年投资组合收款将在32亿美元至32.5亿美元之间，较此前预期上调，预计增长14%至16% [3][22] 财务业绩总结 - 第三季度投资组合收款为8.14亿美元，较2024年同期的7.35亿美元增长11% [4][5][8] - 第三季度特许权使用费收款（Royalty Receipts）为8.11亿美元，较2024年同期的7.32亿美元增长11% [6][8] - 第三季度经营活动提供的净现金为7.03亿美元，与2024年同期基本持平 [4] - 第三季度调整后税息折旧及摊销前利润（Adjusted EBITDA）为7.79亿美元，较2024年同期的6.79亿美元增长15% [4][17] - 第三季度投资组合现金流（Portfolio Cash Flow）为6.57亿美元，较2024年同期的6.17亿美元增长6% [4][17] 资本配置与流动性 - 第三季度资本配置（Capital Deployment）为10.13亿美元，2025年前九个月累计达17.09亿美元 [14][15] - 近期重要交易包括：以高达9.5亿美元收购安进（Amgen）Imdelltra的特许权权益；与Zenas BioPharma就obexelimab达成高达3亿美元的融资协议；以3.1亿美元收购Alnylam的Amvuttra特许权权益 [6][16][21] - 第三季度回购了400万股A类普通股，价值1.52亿美元；2025年前九个月累计回购了3500万股，总价值12亿美元 [6][10] - 截至2025年9月30日，公司拥有现金及现金等价物9.39亿美元，总债务本金为92亿美元，加权平均债务成本为3.75% [9] 投资组合产品表现 - 囊性纤维化（Cystic fibrosis）产品组合：第三季度收款2.22亿美元，同比增长7% [7] - Tremfya：第三季度收款4900万美元，同比增长44% [7] - Xtandi：第三季度收款5000万美元，同比增长15% [7] - Voranigo：第三季度收款3300万美元，去年同期无收入 [7] - Imbruvica：第三季度收款4100万美元，同比下降11% [7] 产品管线关键进展 - Revolution Medicines的daraxonrasib：在一线转移性胰腺癌中获得积极的初步数据，支持在2025年第四季度启动III期临床试验；FDA授予专员国家优先审评券（CNPV）以加速开发和审评 [6][20] - Roche的trontinemab：针对阿尔茨海默病启动了III期临床试验项目 [6][20] - Biogen的litifilimab：针对系统性红斑狼疮的两项III期研究已完成入组，数据读出时间提前至2026年下半年 [20] - Zenas BioPharma的obexelimab：在复发性多发性硬化症的II期试验中显示出阳性结果，预计在2026年第一季度报告24周数据 [20] 行业与市场 - 公司于2025年9月举办了投资者日，强调了特许权市场的快速增长以及公司的竞争优势 [2] - 德勤（Deloitte）发布了关于生物制药特许权市场的首份报告，题为"特许权在资助生物制药创新中的作用"，通过对110多位生物制药行业领袖的调研，分析了当前动态、增长驱动因素和前景 [26]

atai Life Sciences’ shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the Extraordinary General Meeting of Shareholders on November 4, 2025, with approximately 98% of the votes cast at the Extraordinary General Meeting in favor of the transactionsAtaiBeckley has an industry-leading pipeline of investigational treatments, led by BPL-003 (mebufotenin benzoate nasal spray), a Phase 3-ready asset Diversified portfolio also includes Phase 2 ...

Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and ER+ breast cancer; IND-ready in 2026 Robust preclinical anti-tumor activity and favorable tolerability across hematological malignancies differentiate novel, Selective EP300 degrader from dual CBP/EP300 approachesSelec ...

公司近期活动 - 公司将于2025年11月10日太平洋时间下午1:30（东部时间下午4:30）举行电话会议，讨论2025年第三季度财务业绩 [1] - 公司将于同日市场收盘后发布财务业绩和业务更新新闻稿 [1] - 公司还将于2025年11月13日下午4:40至5:10在纽约参加Stifel 2025医疗健康大会并进行演讲，并可安排一对一会议 [2] 公司业务与研发重点 - 公司是一家临床阶段生物技术公司，专注于开发针对肥胖和其他代谢健康疾病的新治疗途径 [3] - 公司战略是通过开发具有临床和商业差异化的同类首创疗法，利用具有大量人体机制验证的生物靶点 [3] - 公司正在为nimacimab进行一项针对肥胖的2期临床试验（ClinicalTrials.gov: NCT06577090），该药物是一种负向变构调节抗体，可外周抑制CB1 [3] - 该研究同时评估nimacimab与GLP-1R激动剂（Wegovy®）的联合用药 [3]

- Company to Host Webcast and Conference Call - BRANFORD, Conn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sachem Capital Corp. (NYSE American: SACH) (the “Company”), a real estate lender specializing in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first mortgages on real property, today announced its financial results for the quarter ended September 30, 2025. John Villano, CPA, Sachem’s Chief Executive Officer, commented, “In the third quarter, amid a challenging macr ...

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint related en ...

Future Relocation and Expansion to Create Up to 100 New Jobs Over 5 Years City Approves Up to $300,000 in Economic Incentives to Rapidly Growing MedTech Business POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the purchase of land for its future headquarters in the Research Park at Florida Atlantic Un ...

~ Provides Fourth Quarter 2025 Guidance ~LONG ISLAND CITY, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Steven Madden, Ltd. (Nasdaq: SHOO), a leading designer and marketer of fashion-forward footwear, accessories and apparel, today announced financial results for the third quarter ended September 30, 2025. Amounts referred to as “Adjusted” are non-GAAP measures that exclude the items defined as “Non-GAAP Adjustments” in the “Non-GAAP Reconciliation” section. Third Quarter 2025 Results Revenue increased 6.9% to ...